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Correlates of Glucagon-Like Peptide-1 Receptor
Agonist Use Among Patients With Atherosclerotic
Cardiovascular Disease and Type 2 Diabetes Mellitus
(from the Department of Veterans Affairs)
Mahmoud Al Rifai, MD, MPHa, Elizabeth M. Vaughan, DO, MPHb,c, Layla A. Abushamat, MD, MPHd,
Michelle Lee, MDe,f, David J. Ramsey, PhDe,f, Kartik Gupta, MDg,
Sankar D. Navaneethan, MD, MSh,i,j, and Salim S. Virani, MD, PhDa,d,e,f,k,*
This study used data from the Veterans Affairs administrative and clinical dataset to evaluate determinants of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among
patients with concomitant atherosclerotic cardiovascular disease and diabetes mellitus
and an antecedent primary care provider visit. The prevalence of GLP-1 RA use was
8.0%. In multivariable-adjusted models, White race, hypertension, obesity, higher hemoglobin A1c, ischemic heart disease, chronic kidney disease, a higher number of primary
care provider visits, and previous cardiology or endocrinology visits were directly associated with GLP-1 RA use. Older age, having a physician primary care provider, and receiving care at a teaching facility were inversely associated with GLP-1 RA use. Our data can
help inform targeted interventions to promote equitable access to GLP-1 RA and incentivize the adoption of these disease-modifying agents in high-risk patient populations. Published by Elsevier Inc. (Am J Cardiol 2022;00:1−4)

Introduction
Recent trends have demonstrated an increasing burden
of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular mortality that is paralleled by a rising prevalence of obesity and type 2 diabetes mellitus.1 Glucagonlike peptide-1 receptor agonists (GLP-1 RAs) have protective cardiovascular effects as shown in recent randomized
clinical trials.2 GLP-1 RAs are also endorsed by the American Diabetes Association for secondary prevention of
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ASCVD and primary prevention in high-risk patients.3 Furthermore, these medications should be considered early in
the treatment strategy in patients with diabetes mellitus,
including as first-line therapy if injectable therapy is warranted to reduce hemoglobin A1c (HbA1c).4 However, few
studies have examined the determinants of GLP-1 RA use
in a contemporary real-world cohort of patients with
ASCVD and diabetes mellitus.5,6 Such data can help inform
policy makers to ensure equitable delivery of these guideline-directed agents, especially among high-risk patients.
Methods
Data for this study were obtained from the nationwide
Veterans Affairs (VA) administrative and clinical dataset.
Veterans ≥18 years old with a diagnosis of ASCVD were
assessed using International Classification of Diseases,
Tenth Revision, Clinical Modification diagnosis and procedure codes and Current Procedural Terminology codes.
Patients were included if they had a primary care provider
(PCP) visit between January 1, 2020 and December 31,
2020 at 130 VA healthcare facilities including VA medical
centers and their associated outpatient community-based
clinics. PCP included both physician and nonphysician
clinicians, including nurse practitioners and physician assistants. This time frame was chosen to evaluate the use of
GLP-1 RA in a contemporary cohort of patients who met
the current criteria for GLP-1 RA, which were approved by
the Food and Drug Administration. Demographics and risk
factors were extracted from the structured VA datasets.
Type 2 diabetes mellitus was defined based on documented
diabetes (2 outpatient or 1 inpatient International Classification of Diseases, Tenth Revision, Clinical Modification
diagnosis code) or HbA1c ≥6.5%, fasting plasma glucose
www.ajconline.org
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≥126 mg/dl, random plasma glucose ≥200 mg/dl, or the use
of diabetes medications within 2 years before the index
visit. Use of GLP-1 RA was assessed using prescription for
the corresponding medications within 180 days before or
up to 100 days after the index PCP visit. GLP-1 RA
included injectables exenatide, liraglutide, lixisenatide,
dulaglutide, and oral semaglutide.
Patients with ASCVD (n = 1,235,567) included those
with a diagnosis of ischemic heart disease (IHD), peripheral
arterial disease, or ischemic cerebrovascular disease identified using well-validated ICD-10 CM diagnosis codes and
Current Procedural Terminology codes.7 Patients with limited life expectancy (receiving hospice care within the preceding 12 months or have a history of metastatic cancer in
the last 5 years) were excluded (n = 32,106). Among the
remaining patients with ASCVD (n = 1,203,461), concomitant type 2 diabetes was identified in 537,980 patients.
The distribution of various demographics and risk factors
was compared by GLP-1 RA use. Multivariable-adjusted
logistic regression models were used to study the association
between patient and facility factors and GLP-1 RA use. A 2sided p <0.05 was used to define statistical significance.
Analyses were conducted using SAS version 9.1.3 (SAS
Institute, Inc., Cary, North Carolina) and Stata version 14
(StataCorp, College Station, Texas). Approval for this study
protocol and a waiver for informed consent were obtained
from the institutional review boards at the Baylor College of
Medicine and the Michael E. DeBakey VA Medical Center.
Results
The study population consisted of 537,980 patients with
concomitant ASCVD and type 2 diabetes: mean (SD) age
72.6 years (9.0), 2.4% women, 70.8% White, 15.3% Black,
and 8.0% were receiving GLP-1 RA. Compared with GLP1 RA nonusers, those who used GLP-1 RA were younger,
more likely to be White, had a higher burden of obesity
(body mass index ≥30 kg/m2), and a lower burden of
peripheral arterial disease in the absence of IHD. However,
GLP-1 RA users had a higher burden of hypertension, IHD,
and systolic heart failure. GLP-1 RA users were more likely
to be receiving insulin, metformin, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors. GLP-1 RA users had a
higher number of PCP visits and were more likely to have
had a cardiology clinic visit or an endocrinology clinic visit
in the 12 months before the index PCP visit (all p <0.01)
(Table 1).
In multivariable-adjusted models, factors directly associated with GLP-1 RA use included White race, hypertension,
obesity, higher HbA1c, IHD, chronic kidney disease, a
higher number of PCP visits, and previous cardiology or
endocrinology visits (Table 2). Older age, having a physician PCP, and receiving care at a teaching facility were
inversely associated with GLP-1 RA use.
Discussion
The present analysis from a VA cohort found that the
utilization rate of GLP-1 RA was low (8.0%), similar to
that reported in a previous study of patients with diabetes
mellitus (7.7%) from a private payer claims database from

2015 to 2019,5 and in the Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) registry (7.9%).6 These
prevalence estimates were less than expected given that the
use of GLP-1 RA has been endorsed by the American Diabetes Association for secondary prevention of ASCVD as
of 2019.3 The use of metformin was also low (58% among
GLP-1 RA users and 46% among nonusers) even though it
is guideline-endorsed for the management of patients with
diabetes mellitus and ASCVD.3 However, the prevalence of
sulfonylurea use was much higher than GLP-1 RA in our
study even though the former is not recommended as a
first-line agent. In addition to the barriers identified in our
study, clinical (therapeutic) inertia may have affected the
adequate uptake of these guideline-endorsed medications.
Previous studies have often cited cost or lack of insurance coverage as a barrier to GLP-1 RA uptake and have
suggested lowering the cost as a potential strategy to
increase the use of GLP-1 RA. However, GLP-1 RA may
not be cost-prohibitive in the VA healthcare system where
copay amounts are generally low. This suggests that factors
beyond cost may hinder adequate uptake of this class of
medications as the present study suggests.
Even after accounting for other demographics and cardiovascular risk factors, non-Whites in our study were less
likely to receive GLP-1 RA, similar to the study by Eberly
et al.5 Based on the present analysis, the reasons for these
racial disparities are unclear; although efforts are warranted
to understand reasons for this disparity to promote equitable
access to GLP-1 RA in all demographic groups.
Patients with more frequent visits to a PCP, cardiologist,
and especially, an endocrinologist were more likely to
receive GLP-1 RA. The presence of an efficient network
with these multiple nodes of care will increase the likelihood
of increased use of these cardioprotective agents by primary
care clinician or specialists. GLP-1 RA were first studied as
glucose-lowering drugs before their cardiovascular benefit
was proved. The significant effect of GLP-1 RA on cardiovascular and renal outcomes must result in expanded use of
these agents. As cardiologists are 5 times more likely to see
patients with concomitant diabetes mellitus and ASCVD
than endocrinologists,8 they are well-positioned to prescribe
these agents, given the high burden of diabetes mellitus and
renal disease in patients with ASCVD. However, the present
study demonstrates that endocrinologists were more likely to
prescribe GLP-1 RA than cardiologists likely because they
are more knowledgeable about this class of medications and
are, therefore, more comfortable prescribing them.
Coordinated efforts including primary care clinicians,
specialists, patients, payers, professional societies, and
health systems must be implemented to promote the adaptation of GLP-1 RA. Educating clinicians about the various
cardiovascular and renal benefits of GLP-1 RA,9,10 in addition to effects on appetite and weight loss,11 may help promote uptake of these medications. Improving knowledge
about injections and management of rare side effects may
also help clinicians be more comfortable prescribing GLP-1
RA. Single or multiple payer systems may also consider the
use of cardioprotective glucose-lowering agents as a performance measure. Lastly, mitigating the barriers and
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Table 1
Baseline characteristics of the study population by GLP-1 RA use
Variable

GLP-1 RA users
n=43,118

GLP-1 RA nonusers
n=494,862

P-value

Age (years), mean (SD)
Men

69.6 (8.0)
41,681 (96.7%)

72.8 (9.0)
483,542 (97.7%)

<0.01
<0.01
<0.01

Non-Hispanic White
Non-Hispanic Black
Other racial/ethnic groups
Hypertension
Body mass index (kg/m2), mean (SD)
Body mass index ≥30 kg/m2
Hemoglobin A1c (%), mean (SD)
Ischemic heart disease (IHD)
Peripheral arterial disease (in the absence of IHD)
Ischemic cerebrovascular disease (in the absence of IHD)
Systolic heart failure
Physician primary care provider
eGFR (ml/min/m2), mean (SD)
eGFR <60 ml/min/m2
Glucose lowering medications
Insulin
Biguanides
Sulfonylureas
Thiazolidinediones
DPP-4 inhibitors
SGLT2- inhibitors
Receipt of care at a teaching facility
Number of PCP visits (primary care) in the 12 months prior to the index PCP visit, mean (SD)
Number of cardiology visits in the 12 months prior to the index PCP visit, mean (SD)
Number of endocrinology visits in the 12 months prior to the index PCP visit, mean (SD)

31,902 (74.0%)
5,374 (12.4%)
5,842 (13.6%)
40,526 (94.0%)
33.9 (6.5)
30,551 (70.9%)
8.0 (1.5)
35,960 (83.4%)
3,506 (8.1%)
4,301 (10.0%)
8,965 (20.8%)
32,461 (75.3%)
62.0 (22.5)
19,780 (45.9%)

349,104 (70.6%)
77,150 (15.6%)
68,608 (13.8%)
447,646 (90.5%)
31.0 (6.2)
258,276 (52.2%)
7.2 (1.4)
391,849 (79.2%)
49,582 (10.0%)
63,112 (12.8%)
80,286 (16.2%)
373,819 (75.5%)
63.8 (22.5)
189 (38.3%)

<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.24
<0.01
<0.01

32,051 (74.3%)
24,813 (57.6%)
9,693 (22.5%)
2,190 (5.1%)
3,084 (7.2%)
12,440 (28.9%)
14,950 (34.7%)
11.0 (7.6)
1.0 (2.3)
0.6 (1.6)

160,407 (32.4%)
229,224 (46.3%)
106,676 (21.6%)
11,913 (2.4%)
48,673 (9.8%)
48,052 (9.7%)
168,309 (34.0%)
7.4 (6.1)
0.7 (1.8)
0.2 (0.8)

<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01

Categorical variables are presented as counts (percentage).
Abbreviations: DPP-4 inhibitors: Dipeptidyl peptidase 4 (DPP-4); SGLT2-inhibitors: Sodium-glucose co-transporter 2 PCP: Primary care provider.

promoting the facilitators identified in our study may help
improve use of these medications in clinical practice.
Reassuringly, higher HbA1c, hypertension, obesity,
IHD, and chronic kidney disease in our study were associated with higher use of GLP-1 RA. In a previous study of
VA patients, we found similar determinants of SGLT-2
inhibitor use except that chronic kidney disease was
inversely associated with the receiving of SGLT-2

inhibitors.7 This suggests that clinicians may be less reluctant to use GLP-1 RA among patients with chronic kidney
disease than SGLT-2 inhibitors.
Clinicians may be reluctant to start GLP-1 RA among
older patients as the present study demonstrates despite that
the effect of GLP-1 RA on major adverse cardiovascular
events does not differ by age as demonstrated in a metaanalysis of randomized controlled trials of GLP-1 RA (p for

Table 2
Multivariate logistic regression analyses for the use of GLP-1 RA in patients with ASCVD and type 2 diabetes
Variable
Age (per 5-year increase)
Women (men as referent)
Race (Whites versus others)
Hypertension
BMI >=30 Kg/m2
Hemoglobin A1c (per 0.5% increase) Scale this one
IHD versus PAD or ICVD only
Physician PCP
eGFR<60 ml/min/m2
Receipt of care at a teaching facility
Number of PCP visits (per PCP visit)
Presence of cardiology visit (Yes/No)
Presence of endocrinology visit (Yes/No)

OR/95% CI

P- value

0.873 (0.867-0.879)
0.99 (0.93-1.06)
1.33 (1.30-1.37)
1.16 (1.10-1.21)
1.83 (1.78-1.87)
1.254 (1.246-1.261)
1.258 (1.222-1.295)
0.96 (0.94-0.99)
1.33 (1.30-1.36)
0.93 (0.91-0.95)
1.056 (1.055-1.057)
1.05 (1.03-1.08)
2.78 (2.71-2.86)

<0.01
0.80
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01

BMI = body mass index; IHD = ischemic heart disease; PAD = peripheral arterial disease; ICVD = ischemic cerebrovascular disease; PCP = primary care
provider; eGFR = estimated glomerular filtration rate.
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interaction = 0.79).2 It is unclear why older patients were
less likely to receive GLP-1 RA; considerations are high
costs, administering drugs through subcutaneous injections,
concern for drug-drug interactions, and concern for risk for
hypoglycemia in older patients. These may discourage prescription of these agents in this patient population. Unexpectedly, having a physician PCP and receiving care at a
teaching facility were associated with lower use of GLP-1
RA. However, there are likely significant variations in practicing patterns across VA facilities in the United States of
which the present study does not evaluate.12
Our results should be interpreted in the context of limitations. We were unable to reliably assess and adjust for additional variables such as doses of respective antidiabetic
medications, which raises the possibility of residual confounding. We could not ascertain whether other risk factors
such as hypertension or hyperlipidemia were adequately
controlled. The majority of our study population consisted
of men and non-Hispanic Whites, which may limit generalizability of our results. Furthermore, we used data from a
single healthcare system, and results may not apply to other
settings. Lastly, our study occurred during the initial phase
of the COVID-19 pandemic when quarantine requirements
may have affected some of our results.
In summary, our study performed in 1 of the largest
health care systems in the United States identified several
barriers and facilitators associated with the use of GLP-1
RA among patients with ASCVD and concomitant type 2
diabetes mellitus.
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